JP2017516811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516811A5 JP2017516811A5 JP2016569985A JP2016569985A JP2017516811A5 JP 2017516811 A5 JP2017516811 A5 JP 2017516811A5 JP 2016569985 A JP2016569985 A JP 2016569985A JP 2016569985 A JP2016569985 A JP 2016569985A JP 2017516811 A5 JP2017516811 A5 JP 2017516811A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- dosage form
- item
- fatty acids
- dha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 49
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 39
- 229930195729 fatty acid Natural products 0.000 claims description 39
- 239000000194 fatty acid Substances 0.000 claims description 39
- 150000004665 fatty acids Chemical class 0.000 claims description 39
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 18
- 150000003626 triacylglycerols Chemical class 0.000 claims description 18
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 13
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 12
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 10
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 10
- 241000238366 Cephalopoda Species 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 101710095342 Apolipoprotein B Proteins 0.000 claims description 4
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 230000035487 diastolic blood pressure Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000000284 resting effect Effects 0.000 claims description 3
- 230000035488 systolic blood pressure Effects 0.000 claims description 3
- 208000010496 Heart Arrest Diseases 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 11
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 9
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 7
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000005886 esterification reaction Methods 0.000 claims 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 claims 2
- 108010042653 IgA receptor Proteins 0.000 claims 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000019198 oils Nutrition 0.000 description 18
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 3
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009145P | 2014-06-06 | 2014-06-06 | |
| US62/009,145 | 2014-06-06 | ||
| US201462019289P | 2014-06-30 | 2014-06-30 | |
| US62/019,289 | 2014-06-30 | ||
| PCT/US2015/034372 WO2015188046A1 (en) | 2014-06-06 | 2015-06-05 | Omega-3 compositions, dosage forms, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020068334A Division JP2020105224A (ja) | 2014-06-06 | 2020-04-06 | ω−３組成物、剤形および使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516811A JP2017516811A (ja) | 2017-06-22 |
| JP2017516811A5 true JP2017516811A5 (enExample) | 2018-07-19 |
| JP6755186B2 JP6755186B2 (ja) | 2020-09-16 |
Family
ID=54767418
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569985A Active JP6755186B2 (ja) | 2014-06-06 | 2015-06-05 | ω−３組成物、剤形および使用法 |
| JP2020068334A Pending JP2020105224A (ja) | 2014-06-06 | 2020-04-06 | ω−３組成物、剤形および使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020068334A Pending JP2020105224A (ja) | 2014-06-06 | 2020-04-06 | ω−３組成物、剤形および使用法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9675575B2 (enExample) |
| EP (2) | EP3151826A4 (enExample) |
| JP (2) | JP6755186B2 (enExample) |
| KR (1) | KR102400958B1 (enExample) |
| CN (1) | CN106687113B (enExample) |
| AU (1) | AU2015269307C1 (enExample) |
| BR (1) | BR112016028561A8 (enExample) |
| CA (1) | CA2950344C (enExample) |
| CL (1) | CL2016003131A1 (enExample) |
| MX (1) | MX2016015791A (enExample) |
| MY (1) | MY186566A (enExample) |
| RU (1) | RU2741965C2 (enExample) |
| TW (1) | TWI725937B (enExample) |
| WO (1) | WO2015188046A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10709680B2 (en) * | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| TWI725937B (zh) * | 2014-06-06 | 2021-05-01 | 美商海洋原料公司 | ω-３組成物、劑型及使用方法 |
| CN110958731A (zh) | 2018-09-21 | 2020-04-03 | 鸿盛国际有限公司 | 发光二极管并联电路 |
| FR3103355B1 (fr) | 2019-11-26 | 2024-05-31 | Polaris | Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés |
| FR3151183A1 (fr) | 2023-07-20 | 2025-01-24 | Microphyt | Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| FR2731015B1 (fr) | 1995-02-24 | 1997-05-30 | Sci Sartone | Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus |
| DE69612011T3 (de) * | 1995-11-24 | 2010-02-18 | Unilever N.V. | Zusammensetzung auf basis von fischöl |
| US7799365B2 (en) * | 2001-04-06 | 2010-09-21 | Burnbrae Farms Limited | Liquid egg composition including fish oil with omega-3 fatty acid |
| US7169385B2 (en) * | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
| SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| US20070020340A1 (en) * | 2005-07-25 | 2007-01-25 | David Rubin | Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension |
| EP1968402A2 (en) | 2005-10-07 | 2008-09-17 | Ocean Nutrition Canada Limited | Salts of fatty acids and methods of making and using thereof |
| EP1968567B1 (en) | 2005-12-20 | 2014-06-18 | Cenestra, Llc | Omega 3 fatty acid formulations |
| US9265745B2 (en) | 2005-12-21 | 2016-02-23 | Brudy Technology S.L. | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
| EP2031985A2 (en) | 2006-06-23 | 2009-03-11 | The Procter and Gamble Company | Concentrated omega-3 fatty acids and mixtures containing them |
| US8410181B2 (en) | 2006-09-19 | 2013-04-02 | The Trustees Of Columbia University In The City Of New York | Omega-3 diglyceride emulsions |
| CA2685272A1 (en) * | 2007-04-26 | 2008-11-06 | Patrick Adlercreutz | A polyunsaturated fatty acid (pufa) enriched marine oil comprising eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), and a process of production thereof |
| US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| CL2008002020A1 (es) | 2007-07-12 | 2008-11-14 | Ocean Nutrition Canada Ltd | Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite. |
| KR101502191B1 (ko) * | 2007-07-30 | 2015-03-12 | 닛폰 스이산 가부시키가이샤 | Ｅｐａ 농축유 및 ｄｈａ 농축유의 제조 방법 |
| KR101045397B1 (ko) | 2008-07-04 | 2011-06-30 | 주식회사동우산업 | 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법 |
| GB0813599D0 (en) | 2008-07-24 | 2008-09-03 | Pharma Marine As | Method |
| US8592439B2 (en) * | 2008-08-07 | 2013-11-26 | Spa Societa Prodotti Antibiotici S.P.A. | Long-term treatment of symptomatic heart failure |
| US20100236137A1 (en) * | 2008-09-23 | 2010-09-23 | LiveFuels, Inc. | Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae |
| CN102421422A (zh) * | 2009-03-09 | 2012-04-18 | 普罗诺瓦生物医药挪威公司 | 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途 |
| CN101695487B (zh) * | 2009-09-22 | 2012-01-18 | 北京百慧生化制药有限责任公司 | 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂 |
| FR2955459B1 (fr) | 2010-01-28 | 2013-11-22 | Polaris | Composition huileuse riche en monoglycerides de dha |
| US20110223246A1 (en) * | 2010-03-10 | 2011-09-15 | Joar Opheim | Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source |
| EP2560633B8 (en) | 2010-04-23 | 2020-08-12 | The Government of the United States, as represented by The Secretary of the Army | Intravenous omega-3 fatty acid compositions & method of use |
| WO2012038833A1 (en) * | 2010-09-24 | 2012-03-29 | Pronova Biopharma Norge As | Process for concentrating omega-3 fatty acids |
| US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
| AU2012347606A1 (en) * | 2011-12-08 | 2014-06-26 | Metaproteomics, Llc | Supplemented oil compositions and methods for improved health |
| TW201343203A (zh) * | 2011-12-22 | 2013-11-01 | 普諾華生物製藥諾治股份有限公司 | 含有ω－３脂肪酸之經明膠／藻酸鹽延緩釋放型膠囊，其製法及用途 |
| AU2013259503B2 (en) | 2012-05-10 | 2017-03-16 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
| WO2014057362A2 (en) | 2012-09-24 | 2014-04-17 | Aker Biopharma As | Omega -3 compositions |
| US20130310457A1 (en) | 2013-07-25 | 2013-11-21 | Niral Ramesh | Solid-in-oil dispersions |
| TWI725937B (zh) | 2014-06-06 | 2021-05-01 | 美商海洋原料公司 | ω-３組成物、劑型及使用方法 |
-
2015
- 2015-06-05 TW TW104118318A patent/TWI725937B/zh active
- 2015-06-05 AU AU2015269307A patent/AU2015269307C1/en active Active
- 2015-06-05 MY MYPI2016704514A patent/MY186566A/en unknown
- 2015-06-05 CA CA2950344A patent/CA2950344C/en active Active
- 2015-06-05 EP EP15803689.7A patent/EP3151826A4/en not_active Ceased
- 2015-06-05 EP EP21157298.7A patent/EP3906920A1/en not_active Ceased
- 2015-06-05 KR KR1020167034160A patent/KR102400958B1/ko active Active
- 2015-06-05 WO PCT/US2015/034372 patent/WO2015188046A1/en not_active Ceased
- 2015-06-05 BR BR112016028561A patent/BR112016028561A8/pt not_active IP Right Cessation
- 2015-06-05 MX MX2016015791A patent/MX2016015791A/es unknown
- 2015-06-05 CN CN201580030195.7A patent/CN106687113B/zh active Active
- 2015-06-05 JP JP2016569985A patent/JP6755186B2/ja active Active
- 2015-06-05 RU RU2016149416A patent/RU2741965C2/ru active
-
2016
- 2016-05-04 US US15/146,680 patent/US9675575B2/en active Active
- 2016-12-05 CL CL2016003131A patent/CL2016003131A1/es unknown
-
2017
- 2017-05-19 US US15/600,124 patent/US10034849B2/en active Active
-
2018
- 2018-06-29 US US16/023,904 patent/US10172819B2/en active Active
-
2019
- 2019-01-04 US US16/240,534 patent/US11160777B2/en active Active
-
2020
- 2020-04-06 JP JP2020068334A patent/JP2020105224A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Borow et al. | Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis | |
| Ismail | The role of omega-3 fatty acids in cardiac protection: an overview | |
| Singh et al. | Microbial production of docosahexaenoic acid (DHA, C22: 6) | |
| US5661180A (en) | Structured lipid containing gama-linolenic or dihogamma-linolenic fatty acid residue, a medium chain (C6 -C12) fatty acid residue, and a n-3 fatty acid residue | |
| JP2007504225A5 (enExample) | ||
| RU2016149416A (ru) | Композиции c омега-3, лекарственные формы и способы их применения | |
| JP2014512351A5 (enExample) | ||
| JP2014517028A5 (enExample) | ||
| RU2019110681A (ru) | Фармацевтическая композиция | |
| Kapoor et al. | Importance and production of omega-3 fatty acids from natural sources. | |
| JP2021137035A5 (ja) | 高度不飽和脂肪酸のトリグリセリドを含む組成物 | |
| JP2574153B2 (ja) | ガン治療用薬剤 | |
| JP2020182497A5 (enExample) | ||
| WO2020244315A1 (zh) | 一种富含多不饱和脂肪酸的甘油酯混合物及其制备方法和应用 | |
| JP2019509344A5 (enExample) | ||
| RU2016116835A (ru) | Способы и композиции для улучшения функции почек | |
| WO2015050071A1 (ja) | 栄養補助剤及び心血管疾患改善剤 | |
| Singer et al. | Different changes of n-6 and n-3 fatty acids in adipose tissue from spontaneously hypertensive (SHR) and normotensive rats after diets supplemented with linolenic or eicosapentaenoic acids | |
| OGUNLEIYE et al. | Effect of fish oil and safflower oil in common Japanese diet on human plasma fatty acid composition | |
| Le Goff et al. | Fatty acids and associated cardiovascular risk | |
| JPH04505100A (ja) | 脂肪製品およびその製造方法 | |
| TWM672733U (zh) | 具有高濃度epa的魚油軟膠囊結構 | |
| TWM659270U (zh) | 含有魚油的軟膠囊結構 | |
| Sandoval et al. | Omega-3 in the Prevention of Cardiovascular Diseases |